Osteonecrosis of the jaws
نویسندگان
چکیده
منابع مشابه
Bisphosphonate-related osteonecrosis of the jaws (Bronj)
UNLABELLED Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is an extremely therapy resistant osteomyelitis-like disease exclusively involving the jaw bones of patients in treatment with bisphosphonates (BPs). OBJECTIVES The aim of this study was to evaluate the radiological and clinical findings and management of 51 patients with BRONJ diagnosed from 2004 to 2009 in our Reference Cen...
متن کاملBiophosphonate-related osteonecrosis of the jaws.
In 2003 and 2004, the first reports of patients who developed necrosis of the jawbones while taking biophosphonates appeared in literature; most patients were on this drug for treatment of cancer and some osteoporosis. Since then, more than 500 cases have been identified and the number of these cases continues to grow. This article reviews the action of bisphosphonates, the condition called bis...
متن کامل[Bisphosphonates and osteonecrosis of the jaws].
The osteonecrosis of the jaws (ONJ) has been reported occasionally in cancer patients treated with radiotherapy and chemotherapy. However, bisphosphonate (BP)-associated ONJ in patients with cancer such as multiple myeloma, breast cancer and prostate cancer mainly administered with intravenous BPs has been first reported in 2003. Since then, many cases over 2,500 are accumulating worldwide. Sin...
متن کاملCould teriparatide be the treatment for osteonecrosis of the jaws?
To the Editor: We read with great interest the case reported by Lee et al in the Early View section of the journal, presenting a case of aledronate-induced osteonecrosis of the jaws (ONJ), which healed following teriparatide administration. The authors conclude that teriparatide can be an important adjuvant to other measures in the management of ONJ that should be considered prior to major rese...
متن کاملThe relationship of denosumab pharmacology and osteonecrosis of the jaws.
Denosumab is a new bone antiresorptive agent that has received approval by the Food and Drug Administration for use in patients with osteoporosis and metastatic cancer to the bones. Like the bisphosponates that are used as antiresorptive medications, denosumab has been associated with osteonecrosis of the jaws (ONJ). However, because the pharmacodynamics and pharmacokinetics of denosumab differ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2015
ISSN: 1462-0324,1462-0332
DOI: 10.1093/rheumatology/kev094